Impact Biomedical Inc. (IBO) Financial Statements
Industry: Pharmaceutical Preparations
In fiscal 2025, Impact Biomedical reported revenue of $32,000. Net income was -$11.8M (a -36993.8% net margin), or -$4.81 per diluted share. Gross margin was -1225.0% and operating margin was -13381.2%. Operating activities generated -$1.9M of cash. At fiscal year end, Impact Biomedical held $17.4M in total assets against $1.9M in total liabilities, including $3,000 of cash and equivalents.
Open the full interactive Impact Biomedical financials → Quarterly statements, key ratios, valuation history and price charts.
Impact Biomedical Key Stats
| Share Price | $3.98 |
|---|---|
| Market Cap | $33.9M |
| 52-Week Range | $3.98 – $9.87 |
| Shares Outstanding | 8.5 million (basic, 2026 Q2) |
Impact Biomedical Income Statement
| FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|
| Revenue | — | $0 | $32,000 |
| Cost of Goods Sold | $4.0M | — | $424,000 |
| Gross Profit | -$4.0M | — | -$392,000 |
| Operating Income | -$4.0M | -$28.8M | -$4.3M |
| Pre-Tax Income | -$4.4M | -$24.7M | -$14.4M |
| Income Tax | — | $33,000 | -$2.6M |
| Net Income | -$4.4M | -$24.7M | -$11.8M |
| Diluted EPS | -$0.89 | -$29.11 | -$4.81 |
Impact Biomedical Quarterly Results
| 2025 Q3 | 2025 Q4 | 2026 Q1 | 2026 Q2 | |
|---|---|---|---|---|
| Revenue | $18,000 | $7,000 | $7,000 | $3,000 |
| Net Income | -$1.5M | $5.2M | -$2.3M | -$699,000 |
| Diluted EPS | -$1.52 | — | -$0.25 | -$0.13 |
Impact Biomedical Balance Sheet
| FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|
| Cash & Equivalents | $1,000 | $2.0M | $3,000 |
| Current Assets | $332,000 | $2.4M | $411,000 |
| Total Assets | $44.6M | $20.3M | $17.4M |
| Current Liabilities | $13.1M | $9.8M | $1.2M |
| Total Liabilities | $16.4M | $13.1M | $1.9M |
| Shareholders' Equity | $25.2M | $4.3M | $12.6M |
Impact Biomedical Cash Flow Statement
| FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|
| Cash From Operations | -$2.9M | -$3.9M | -$1.9M |
| Cash From Investing | -$15,000 | $2,000 | $3,000 |
| Cash From Financing | $2.9M | $5.9M | -$109,000 |
Figures from Impact Biomedical's 10-K and 10-Q filings with the SEC, as of 2026-10-14. Fiscal years follow the company's own reporting calendar. EPS and share counts are adjusted for later stock splits. See the full Impact Biomedical financials page for every line item.
Impact Biomedical Company Profile
| Ticker | IBO |
|---|---|
| Exchange | NYSE |
| Industry | Pharmaceutical Preparations |
| Headquarters | Houston, Texas |
| Incorporated in | Nevada |
| Fiscal Year End | December 31 |
| SEC Filer Category | Non-accelerated filer, smaller reporting company, emerging growth company |
| SEC CIK | 0001834105 |
Frequently Asked Questions
What was Impact Biomedical's revenue in fiscal 2025?
Impact Biomedical (IBO) reported revenue of $32,000 for fiscal 2025.
What was Impact Biomedical's net income in fiscal 2025?
Impact Biomedical reported net income of -$11.8M for fiscal 2025.
What was Impact Biomedical's earnings per share (EPS) in fiscal 2025?
Impact Biomedical's diluted EPS was -$4.81 for fiscal 2025 (adjusted for any later stock splits).
What was Impact Biomedical's revenue last quarter?
In its most recent reported quarter (2026 Q2), Impact Biomedical reported revenue of $3,000.
How many shares of Impact Biomedical are outstanding?
Impact Biomedical reported a weighted average of 8.5 million basic shares outstanding in 2026 Q2.
What is Impact Biomedical's market cap?
Based on its latest closing price, Impact Biomedical (IBO) has a market capitalization of about $33.9M.
When does Impact Biomedical's fiscal year end?
Impact Biomedical's fiscal year end, as registered with the SEC, is December 31.
Where is Impact Biomedical headquartered?
Impact Biomedical lists its business address in Houston, Texas in its SEC filings.